Program
deudomperidone
Also written as “CIN-102 Dose 1”, “CIN-102 Dose 2” and “CIN-102 Dose 15mg or 10mg”.
Its studies are mostly in Gastroparesis, led by CinDome Pharma.
Furthest: phase 2, since Jul 17, 20194 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CinDome Pharma | 40 open or running | phase 2since Jul 17, 2019 | Jul 17, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2019First study: phase 2 study in GastroparesisFirst studyNCT04026997 · 72 enrolled · United States
- Dec 12, 2019Phase 2 study in Diabetic GastroparesisNCT04208698 · 2 enrolled · United States
- Mar 16, 2023Phase 2 study in GastroparesisNCT05832151 · 382 enrolled · United States
- Feb 14, 2025Phase 2 study in GastroparesisNCT06899217 · 416 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06899217Gastroparesis · United States | 2 | Completed | May 7, 2026 | 416 |
| NCT05832151Gastroparesis · United States | 2 | Completed | Nov 14, 2025 | 382 |
| NCT04208698Diabetic Gastroparesis · United States | 2 | Terminated | Mar 31, 2020 | 2 |
| NCT04026997Gastroparesis · United States | 2 | Terminated | Dec 17, 2020 | 72 |
How it is read
Names in the registry
- “CIN-102 Dose 1”, 2 entries
- “CIN-102 Dose 2”, 2 entries
- “CIN-102 Dose 15mg or 10mg”, 1 entry
- “CIN-102 Dose 15mg”, 1 entry
- “CIN-102 Dose 10mg”, 1 entry
Conditions, from the studies’ own filings
- Gastroparesis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.